INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 411m ago
HOUSE PTR10m ago
SEC 13F10m ago
ROBINHOOD CHAIN10m ago
Corporate insider
MA

McGeorge Anne

DirectorCIK 0001779934

EDGAR filingsOpen in network
Disclosed transactions9
Buys / sells0 / 5
Max Insider Score25
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
25
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$111K
1,000 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Dianthus Therapeutics, Inc. /DE/Director · Aug 11, 2026
25
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL
$78K
700 sh
Aug 10, 2026
Aug 11, 2026
traded Aug 10, 2026
+1d
SEC FORM 4

Evidence

0
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$24K
1,250 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

14
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$73K
6,500 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

17
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$156K
1,450 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

24
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$303K
2,800 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

25
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$197K
1,800 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

0
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
1,250 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

0
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
6,500 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence